Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Sees Large Decrease in Short Interest

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totaling 25,732 shares, a drop of 58.6% from the August 31st total of 62,228 shares. Based on an average daily trading volume, of 500 shares, the short-interest ratio is currently 51.5 days.

Analysts Set New Price Targets

Separately, Danske initiated coverage on shares of Hansa Biopharma AB (publ) in a research report on Tuesday, June 16th. They set a “buy” rating for the company. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Hansa Biopharma AB (publ) Stock Up 13.4%

Shares of OTCMKTS HNSBF traded up $0.39 during midday trading on Tuesday, hitting $3.29. The company had a trading volume of 6,000 shares, compared to its average volume of 7,550. Hansa Biopharma AB has a twelve month low of $2.90 and a twelve month high of $3.70. The business has a 50-day simple moving average of $3.59 and a two-hundred day simple moving average of $3.14.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ) is a Swedish biotechnology company focused on developing and commercializing treatments for rare immunological conditions. The company’s technology is designed to selectively modulate the immune system, with the goal of enabling medical procedures and addressing diseases in which pathogenic antibodies play a significant role.

Its leading product is Idefirix (imlifidase), an enzyme therapy that rapidly cleaves immunoglobulin G antibodies. Idefirix is approved in the European Union for desensitization treatment of highly sensitized adult kidney transplant patients who are unlikely to receive a transplant under the available kidney allocation system.